Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of “Buy” by Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been assigned an average recommendation of “Buy” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $107.00.

A number of research firms recently issued reports on MNPR. BTIG Research increased their target price on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Raymond James Financial cut shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and decreased their price target for the stock from $142.00 to $123.00 in a research note on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Wednesday, October 8th. Oppenheimer set a $115.00 price objective on Monopar Therapeutics and gave the company an “outperform” rating in a report on Thursday, October 2nd. Finally, Leerink Partners assumed coverage on Monopar Therapeutics in a report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price on the stock.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $67.04 on Friday. The firm’s 50 day simple moving average is $75.33 and its 200 day simple moving average is $62.89. Monopar Therapeutics has a fifty-two week low of $24.00 and a fifty-two week high of $105.00. The company has a market capitalization of $447.83 million, a price-to-earnings ratio of -19.49 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Equities research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Activity

In other news, CFO Quan Anh Vu bought 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was acquired at an average cost of $69.95 per share, for a total transaction of $104,925.00. Following the purchase, the chief financial officer owned 1,500 shares of the company’s stock, valued at approximately $104,925. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics during the 3rd quarter valued at $28,000. BNP Paribas Financial Markets lifted its stake in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics during the 2nd quarter worth about $34,000. AlphaQuest LLC boosted its holdings in shares of Monopar Therapeutics by 46.8% during the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after buying an additional 569 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the last quarter. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.